STAT

SEPTEMBER 23, 2022

These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025. According to the most recent “U.S.

Biosimilars 240

Biosimilars Diabetes Drug Pricing 240

The Pharmacist

APRIL 21, 2023

Up to one in 20 new cases of diabetes could be linked to Covid infection, a large study has concluded. But people who were vaccinated against Covid did not have a higher risk of diabetes.

Diabetes 98

Diabetes Vaccines 98

pharmaphorum

DECEMBER 21, 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

pharmaphorum

MARCH 25, 2021

The other side of 2020 for Boehringer was the impact of the pandemic on its medicine sales, although the company managed to keep revenues in positive territory with a 3% increase to €19.57 The big revenue contributor was diabetes drug Jardiance (empagliflozin), which grew 15% to €2.48 billion ($23.11

Diabetes 98

Diabetes Hospitals 98

Express Pharma

APRIL 27, 2023

Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData.

Diabetes 93

Diabetes 93

Med Ed 101

NOVEMBER 22, 2020

Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The post Two Diabetes Updates in 2020 appeared first on Med Ed 101.

Diabetes 40

Diabetes 40

Express Pharma

NOVEMBER 3, 2023

Saroglitazar Mg was launched in India in September 2013 for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. It reduces co-morbidities (dyslipidemia, hypertriglyceridemia, and diabetes mellitus).

Diabetes 111

Diabetes 111

Drug Channels

JULY 29, 2020

In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis. d/b/a Drug Channels Institute.

Diabetes 52

Diabetes Biosimilars 52

ALiEM - Pharm Pearls

FEBRUARY 9, 2024

Let’s apply the ESC 2020 0/1 hour pathway [2], with some modifications based on the 2022 ACC guidelines [1]: Figure 1. Case #2 A 66-year-old man with hypertension, hyperlipidemia, diabetes mellitus, and chronic renal failure presents with poorly localized central chest discomfort while trying to sleep. It started 2 hours ago.

Hospitals 276

Hospitals Diabetes 276

Express Pharma

OCTOBER 18, 2023

It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes. According to IQVIA sales data for the 12‐month period ending August 2023 (MAT August 2023), the market for oral anti‐diabetic drugs in India is estimated to be Rs 12,522 crores, with an annual growth of 6.5

Diabetes 105

Diabetes 105

pharmaphorum

NOVEMBER 8, 2022

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.

Diabetes 64

Diabetes Communication 64

pharmaphorum

SEPTEMBER 1, 2020

AZ halted DAPA-CKD in July after revealing that Farxiga (dapagliflozin) met its objective of slowing the worsening of renal function and cut the risk of death in patients with chronic kidney disease (CKD) with and without type 2 diabetes. . The post AZ trumpets Farxiga survival data in renal disease at ESC 2020 appeared first on.

Diabetes 52

Diabetes 52

pharmaphorum

OCTOBER 26, 2020

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the phase 3 FIDELIO-DKD trial. Diabetes is the leading cause of kidney failure, and there are estimated to be almost 850 million people worldwide with chronic kidney disease (CKD).

Diabetes 98

Diabetes 98

pharmaphorum

AUGUST 6, 2021

The pandemic contributed to another 90,000 apps being introduced in 2020 – an average of 250 per day – and this coupled with rising number and functionality of wearable devices “provides evidence of digital health’s accelerating innovation,” according to the IQVIA Institute for Human Data Science’s 2021 trends report.

Diabetes 145

Diabetes 145

pharmaphorum

AUGUST 24, 2020

What current topic will you be addressing in your presentation, and what would you say makes it relevant to 2020? “We 23 rd -24 th November 2020. The post Exclusive interview with ForwardVue Pharma released for Ophthalmic Drugs 2020 appeared first on. Ophthalmic Drugs Conference. OphthalmicDrugs. or call +44 (0)20 7827 6088.

Packaging 52

Packaging Diabetes 52

pharmaphorum

JANUARY 24, 2023

Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450 million at a facility in North Carolina that will make the drug. billion since 2020. That comparison was however made before Novo Nordisk launched a higher-strength version of its drug.

Diabetes 97

Diabetes Packaging 97

pharmaphorum

JUNE 28, 2022

The two companies first started working together in 2020, initially focusing on Health2Sync’s home market of Taiwan, bundling the software with Sanofi’s insulin therapies at clinics across the country. The post Sanofi extends Health2Sync digital diabetes partnership to Japan appeared first on.

Diabetes 52

Diabetes Communication 52

pharmaphorum

JANUARY 31, 2022

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients, and has now added artificial intelligence capabilities with an agreement to acquire xbird. billion deal in 2020. The post Glooko adds AI to its digital diabetes tools with xbird takeover appeared first on.

Diabetes 52

Diabetes 52

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. The lower injection frequency might also encourage type 2 diabetics to start insulin treatment earlier, and help stave off the damaging complications of the disease.

Diabetes 98

Diabetes 98

pharmaphorum

NOVEMBER 15, 2021

It enrolled patients with and without type 2 diabetes and heart failure, to see whether treatment with Invokana (canagliflozin) can improve their symptoms, function and quality of life compared to placebo. billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Diabetes 105

Diabetes Labelling 105

The Pharmacist

JUNE 6, 2024

Atorvastatin was once again the most dispensed chemical substance by community pharmacies in England last year, while the number of items dispensed has continued to increase year on year since 2020/21.

Community Pharmacies 129

Community Pharmacies Diabetes 129

Pharmaceutical Technology

JANUARY 22, 2023

The company stated that the drug received Fast Track designation from the US FDA for the same indication in March 2020. Jardiance was initially approved in 2014 as a once-a-day tablet for use with diet and exercise to reduce blood sugar in type 2 diabetes adult patients.

Diabetes 105

Diabetes 105

Drug Patent Watch

JANUARY 13, 2025

from 2020 to 2025[1]. ” Diabetes: Addressing a Global Epidemic With diabetes affecting millions worldwide, the advent of biosimilar insulins has been particularly impactful. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4

Biosimilars 78

Biosimilars Diabetes 78

Amber

NOVEMBER 21, 2022

21, 2022) – Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. OMAHA, Neb.

Specialty Pharmacies 52

Specialty Pharmacies Diabetes 52

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

66 year-old-male with a history of type 2 diabetes and hypertension presented as a transfer for rapid progression of lower extremity pain, swelling, and blue-purple discoloration of the entire limb with concern for a possible necrotizing infection. Epub 2020 Nov 25. He had no known thromboembolic risk factors. Phlebology.

Medical Schools 152

Medical Schools Diabetes 152

Pharmaceutical Technology

JULY 15, 2022

The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). In-house manufacturing the norm.

Biosimilars 131

Biosimilars Diabetes Documentation Packaging 131

Express Pharma

NOVEMBER 12, 2023

In March 2022, desidustat was approved in India to treat anemia associated with chronic kidney disease (CKD), whereas saroglitazor was approved in June 2013 for diabetic dyslipidemia and hypertriglyceridemia. Moreover, saroglitazar is the world’s first drug to get approval for NASH.

Diabetes 105

Diabetes 105

pharmaphorum

JUNE 22, 2021

Jardiance, Farxiga (dapagliflozin) and other SGLT2 drugs are already widely used to treat type 2 diabetes, and their developers have long had aspirations to expand their use into other cardiometabolic disorders, including heart failure and chronic kidney disease (CKD).

Diabetes 98

Diabetes 98

Pharmafile

JANUARY 26, 2023

Published date: 26/01/2023 Summary: 26 January 2023 Galway, Ireland - Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). read more

Diabetes 40

Diabetes 40

pharmaphorum

SEPTEMBER 14, 2021

“We’re seeing evidence of the enormous potential in some of the recent telehealth success stories in the USA such as Teladoc and Livongo, the former a remote teleconsultation service focused on primary care, the latter a platform for remote support of chronic diseases that started in diabetes.”.

Diabetes 135

Diabetes Online Pharmacies Medical Records Hospitals 135

European Pharmaceutical Review

MAY 27, 2024

These treatments are indicated for obesity and type 2 diabetes. Manufacturing for the future The company highlighted that it has committed over $16 billion to develop new manufacturing sites in the US and Europe since 2020, including in a biologic facility in Limerick, Ireland. This new $5.3 These include a $1.2

Diabetes 105

Diabetes 105

Board Vitals - Pharmacist

DECEMBER 29, 2022

Jen Trachtenberg (@askdrjen) on Sep 24, 2020 at 3:41pm PDT. doctor.mike) on Sep 29, 2020 at 6:54am PDT. A post shared by Suchismita (Tia) Paul, MD (@drspaulderm) on Sep 18, 2020 at 7:55am PDT. A post shared by Nii-Daako Darko, DO, MBA, FACS (@drniidarko) on Aug 17, 2020 at 5:05am PDT. Mike Varshavski, MD. doctor.mike .

Hospitals 98

Hospitals Medical Schools Inpatient Diabetes 98

pharmaphorum

JANUARY 12, 2021

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.

Labelling 76

Labelling Diabetes 76

pharmaphorum

JANUARY 9, 2022

The aim is to decode the messages that are being sent by the body, with the project growing out of the platform that Abbott has already developed for continuous glucose monitoring in people with diabetes. That builds on Abbott’s already-launched glucose biowearable – Libre Sense Glucose Sport – which was launched in Europe in 2020.

Diabetes 145

Diabetes 145

pharmaphorum

JANUARY 5, 2021

Healthcare systems ended 2020 in a very different place to where they were in 2019, with hospital capacity (and hospital finances) challenges. Throughout 2020, IQVIA data, both secondary and primary research pointed to often substantial share of non-COVID-19 patients receiving no, or suboptimal treatment.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98